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Immune checkpoints blockade inhibitors, such as anti-
CTLA-4 and anti-PD-1, are now proven effective cancer
treatments. In melanoma, the patients who experience
clinical benefits usually have T cell-inflamed tumor
microenvironment. Understanding the molecular
mechanism explaining lack of T cell infiltration in a
major subset of patients should lead to development of
new therapeutic strategies that improve spontaneous
T cell infiltration into tumors and render these patients
responsive to immunotherapies. It has been proposed
that the T cell-inflamed (hot) and non-T cell inflamed
(cold) phenotypes might be due to the differential
expression of immunogenic antigens. To test this
hypothesis, we compared the levels of three types of
antigens: cancer-testis (CT) antigens, differentiation
antigens, and somatic mutational antigens, in hot and
cold tumors.
Using the TCGA data set for malignant melanoma, the
patients were segregated according to the presence or
absence of the T cell-inflamed gene expression signature
in the tumor microenvironment. Transcriptional profiling
revealed no differences in the levels of cancer-testis (CT)
antigens or differentiation antigens between the hot and
the cold tumors. Using exome sequencing of tumor versus
germline, a range of 18 to 3001 of non-synonymous muta-
tions was observed in both cohorts. Using the syfpeithi
algorithm for HLA-A*0201 patients, a median of 123
mutations having a high immunogenicity score were
found in the T cell-inflamed cohort versus 176 in the non-
T cell-inflamed. To confirm actual immunogenicity, 321
peptides from hot tumors and 409 peptides from cold
tumors have been synthesized. Using a high-throughput
T2 binding assay, peptides from both cohorts were found
to bind to HLA-A*0201. In vitro priming of T cells using
autologous dendritic cells also revealed that peptides from
both cohorts could prime human antigen-specific CD8+
T cells. Our results indicate that there is not a lack ofim-
munogenic antigens in non-T cell-inflamed melanomas.
Other mechanisms must explain T cell exclusion in those
cases, such as the recently described Wnt/b-catenin path-
way activation. New strategies to promote T cell entry into
non-inflamed tumors have a chance for success if immu-
nogenic antigens are indeed present and can be accessed
by host immune cells.
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